Generic Accutane risk management
Executive Summary
FDA is still considering risk management requirements for generic versions of Roche's Accutane (isotretinoin), the agency says in an Aug. 12 response to a Roche citizen petition. "FDA has been unable to reach a decision on your petition because it raises significant issues requiring extensive review and analysis," the agency said. Mylan's isotretinoin ANDA has been held up by discussions on risk management, but the company told analysts July 25 that Mylan has "addressed all outstanding issues" with FDA and looks "forward to an approval" (1"The Pink Sheet" August 5, In Brief)...
You may also be interested in...
Mylan generic Accutane launch
Mylan has "addressed all outstanding issues" with FDA over a generic isotretinoin launch and is "prepared to comply with all risk management program requirements before us," Senior VP Jim Mauzey says. "Our sales representatives are trained on the product, and our wholesalers and retail customer base has been contacted and presented with our program for introduction. We look forward to an approval." The ANDA has been held up by discussions regarding appropriate risk management for Accutane (1"The Pink Sheet" March 11, p. 16)...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.